ArticleParkinsonism & related disorders2025
Relationships between neuronal loss, age of death, disease duration and MRI brain volumes in progressive supranuclear palsy.
Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeuronal loss and the presence of tau lesions in specific brain regions is required for a definitive diagnosis of progressive supranuclear palsy (PSP). We previously found tau burden in basal ganglia and red nucleus to be associated with disease duration and age at death. It is currently unknown whether neuronal loss is also associated with disease duration and age at death, or with antemortem brain volume loss in PSP.
objectiveTo investigate whether neuronal loss is associated with tau burden, age at death, disease duration, or brain volume loss in PSP.
methodsForty-one pathologically confirmed PSP participants prospectively recruited and followed by the Neurodegenerative Research Group (NRG), Mayo Clinic, MN, between 2009 and 2023, of which 40 completed antemortem MRI, were analyzed. Neuronal loss in the subthalamic and red nuclei was determined on hematoxylin and eosin. Multinomial logistic regressions with age at death, disease duration, and brain volume as independent variables, and regional neuronal loss as outcome, were performed.
resultsFourteen participants (34 %) were female, median age at death was 74 years [68, 79], and median disease duration was 8.2 years [5.7, 9.9]. Greater neuronal loss was associated with greater burden of glial, but not neuronal, tau lesions in both nuclei. Greater neuronal loss was associated with shorter disease duration in both nuclei, particularly in the subthalamic nucleus, and smaller volume on MRI of the red nucleus.
conclusionsNeuronal loss in subthalamic and red nuclei, cardinal PSP regions, appear to be playing a role in disease duration and brain volume loss in PSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.